Tandem Diabetes Care, Inc. $TNDM Holdings Raised by Intech Investment Management LLC

Intech Investment Management LLC raised its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 55.2% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 73,493 shares of the medical device company’s stock after buying an additional 26,150 shares during the period. Intech Investment Management LLC’s holdings in Tandem Diabetes Care were worth $892,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Hood River Capital Management LLC raised its holdings in shares of Tandem Diabetes Care by 10.9% during the second quarter. Hood River Capital Management LLC now owns 2,564,978 shares of the medical device company’s stock worth $47,811,000 after acquiring an additional 252,934 shares in the last quarter. Paradice Investment Management LLC boosted its position in Tandem Diabetes Care by 24.3% during the third quarter. Paradice Investment Management LLC now owns 2,196,468 shares of the medical device company’s stock valued at $26,665,000 after purchasing an additional 429,289 shares during the last quarter. Geode Capital Management LLC grew its stake in Tandem Diabetes Care by 3.2% in the second quarter. Geode Capital Management LLC now owns 1,606,336 shares of the medical device company’s stock valued at $29,946,000 after purchasing an additional 49,126 shares in the last quarter. Ophir Asset Management Pty Ltd acquired a new position in Tandem Diabetes Care in the 2nd quarter worth about $27,307,000. Finally, Champlain Investment Partners LLC increased its position in Tandem Diabetes Care by 6.3% in the 2nd quarter. Champlain Investment Partners LLC now owns 1,455,123 shares of the medical device company’s stock worth $27,123,000 after purchasing an additional 86,235 shares during the last quarter.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ TNDM opened at $21.14 on Monday. The business’s 50-day simple moving average is $21.40 and its 200-day simple moving average is $18.02. The company has a debt-to-equity ratio of 2.00, a quick ratio of 2.02 and a current ratio of 2.55. Tandem Diabetes Care, Inc. has a 52 week low of $9.98 and a 52 week high of $29.65. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -6.89 and a beta of 1.62.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Thursday, February 19th. The medical device company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.04. Tandem Diabetes Care had a negative return on equity of 68.23% and a negative net margin of 20.17%.The company had revenue of $290.38 million for the quarter, compared to the consensus estimate of $277.14 million. During the same quarter last year, the company posted $0.01 earnings per share. The company’s revenue for the quarter was up 15.1% compared to the same quarter last year. As a group, equities research analysts expect that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on TNDM shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Tandem Diabetes Care in a report on Wednesday, January 21st. Lake Street Capital raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a research report on Monday, February 23rd. Citigroup lifted their target price on shares of Tandem Diabetes Care from $16.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, December 11th. Truist Financial reissued a “hold” rating and issued a $27.00 target price (up from $24.00) on shares of Tandem Diabetes Care in a research report on Monday, February 23rd. Finally, Mizuho set a $22.00 price target on shares of Tandem Diabetes Care and gave the stock a “neutral” rating in a research note on Friday, February 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $28.11.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc (NASDAQ: TNDM), headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company’s flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.